Insider Selling: Liquidia Co. (NASDAQ:LQDA) CFO Sells $43,240.12 in Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,892 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the transaction, the chief financial officer now directly owns 311,076 shares in the company, valued at $3,456,054.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Michael Kaseta also recently made the following trade(s):

• On Tuesday, September 3rd, Michael Kaseta sold 1,079 shares of Liquidia stock. The stock was sold at an average price of $9.50, for a total value of $10,250.50.

Liquidia Trading Down 1.5 %

Shares of NASDAQ:LQDA opened at $11.46 on Friday. The firm has a 50 day simple moving average of $10.42 and a 200-day simple moving average of $11.97. Liquidia Co. has a twelve month low of $5.71 and a twelve month high of $16.99. The company has a market capitalization of $875.70 million, a PE ratio of -7.35 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The company had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. As a group, equities research analysts predict that Liquidia Co. will post -1.69 EPS for the current fiscal year.

Analysts Set New Price Targets

LQDA has been the subject of several analyst reports. BTIG Research dropped their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Bank of America cut their price target on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Scotiabank initiated coverage on Liquidia in a research note on Wednesday. They issued a “sector outperform” rating and a $30.00 price objective on the stock. HC Wainwright reduced their target price on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Finally, Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Institutional Trading of Liquidia

Large investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in Liquidia in the second quarter valued at approximately $27,000. Hilltop National Bank acquired a new position in Liquidia in the second quarter valued at $33,000. Whitcomb & Hess Inc. raised its holdings in shares of Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after buying an additional 1,074 shares during the last quarter. Deuterium Capital Management LLC purchased a new position in shares of Liquidia during the second quarter worth about $120,000. Finally, DMC Group LLC purchased a new stake in Liquidia during the 2nd quarter valued at approximately $122,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).